PE20171650A1 - Derivados de tetrahidropiranil benzamida - Google Patents
Derivados de tetrahidropiranil benzamidaInfo
- Publication number
- PE20171650A1 PE20171650A1 PE2017001456A PE2017001456A PE20171650A1 PE 20171650 A1 PE20171650 A1 PE 20171650A1 PE 2017001456 A PE2017001456 A PE 2017001456A PE 2017001456 A PE2017001456 A PE 2017001456A PE 20171650 A1 PE20171650 A1 PE 20171650A1
- Authority
- PE
- Peru
- Prior art keywords
- imidazol
- dimethyl
- methyl
- chiral
- tetrahydropyranil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
Referida a un compuesto de formula 1, donde: R es NH u O; R1 es -CF3, -OCF3 o halogeno; R2 es 1,4-dimetil-1H-imidazol-5-il; 1-ciclobutil-4-metil-1H-imidazol-5-il; entre otros; R3 es alquilo C1-C3 o ciclopropilo y cada asterisco designa un centro quiral. Son compuestos preferidos: Cis-(quiral)-N-[(2-[5-(1,4-dimetil-1H-imidazol-5-il)-4H-1,2,4-triazol-3-il]tetrahidro-2H-piran-4-il]-N-metil-3-(trifluorometil)benzamida isomero 1; Cis-(quiral)-3-cloro-N-[(2-[5-(1,4-dimetil-1H-imidazol-5-il)-4H-1,2,4-triazol-3-il]tetrahidro-2H-piran-4-il]-N-metil-benzamida isomero 1; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son agonistas de GPR142, siendo utiles en la reduccion de los niveles de glucosa en plasma o sangre.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/073563 WO2016138631A1 (en) | 2015-03-03 | 2015-03-03 | Imidazo benzamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171650A1 true PE20171650A1 (es) | 2017-11-13 |
Family
ID=56849060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001456A PE20171650A1 (es) | 2015-03-03 | 2016-02-19 | Derivados de tetrahidropiranil benzamida |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10196385B2 (es) |
| EP (1) | EP3265460A4 (es) |
| JP (1) | JP2018507232A (es) |
| KR (1) | KR20170106483A (es) |
| CN (1) | CN107406436B (es) |
| AU (1) | AU2016228055B2 (es) |
| BR (1) | BR112017015448A2 (es) |
| CA (1) | CA2975413A1 (es) |
| CL (1) | CL2017002148A1 (es) |
| CO (1) | CO2017008721A2 (es) |
| CR (1) | CR20170354A (es) |
| DO (1) | DOP2017000196A (es) |
| EA (1) | EA201791745A1 (es) |
| EC (1) | ECSP17058071A (es) |
| IL (1) | IL253405A0 (es) |
| MA (1) | MA41641A (es) |
| MX (1) | MX2017011087A (es) |
| PE (1) | PE20171650A1 (es) |
| PH (1) | PH12017501560A1 (es) |
| SG (1) | SG11201706718RA (es) |
| SV (1) | SV2017005520A (es) |
| TN (1) | TN2017000372A1 (es) |
| WO (2) | WO2016138631A1 (es) |
| ZA (1) | ZA201704948B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014337A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide |
| CN111902413B (zh) | 2018-03-09 | 2023-10-17 | 里科瑞尔姆Ip控股有限责任公司 | 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010505957A (ja) | 2006-10-10 | 2010-02-25 | アムゲン インコーポレイティッド | 糖尿病に対して使用されるｎ−アリールピラゾール化合物 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP5685181B2 (ja) * | 2009-03-05 | 2015-03-18 | 塩野義製薬株式会社 | Ｎｐｙｙ５受容体拮抗作用を有するシクロヘキサン誘導体 |
| EP2523558A4 (en) * | 2010-01-15 | 2013-06-19 | Merck Sharp & Dohme | BETA-CARBOLINE OXADIAZOLE DERIVATIVES AS ANTIDIABETIC COMPOUNDS |
| WO2012123449A1 (en) * | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| WO2015120610A1 (en) | 2014-02-14 | 2015-08-20 | Eli Lilly And Company | Gpr142 agonist compound |
-
2015
- 2015-03-03 WO PCT/CN2015/073563 patent/WO2016138631A1/en active Application Filing
-
2016
- 2016-02-18 MA MA041641A patent/MA41641A/fr unknown
- 2016-02-19 CR CR20170354A patent/CR20170354A/es unknown
- 2016-02-19 US US15/118,295 patent/US10196385B2/en active Active
- 2016-02-19 JP JP2017546161A patent/JP2018507232A/ja active Pending
- 2016-02-19 MX MX2017011087A patent/MX2017011087A/es unknown
- 2016-02-19 BR BR112017015448A patent/BR112017015448A2/pt not_active IP Right Cessation
- 2016-02-19 PE PE2017001456A patent/PE20171650A1/es not_active Application Discontinuation
- 2016-02-19 WO PCT/CN2016/074083 patent/WO2016138821A1/en active Application Filing
- 2016-02-19 AU AU2016228055A patent/AU2016228055B2/en not_active Expired - Fee Related
- 2016-02-19 CN CN201680013049.8A patent/CN107406436B/zh active Active
- 2016-02-19 EP EP16758437.4A patent/EP3265460A4/en not_active Withdrawn
- 2016-02-19 TN TNP/2017/000372A patent/TN2017000372A1/en unknown
- 2016-02-19 EA EA201791745A patent/EA201791745A1/ru unknown
- 2016-02-19 SG SG11201706718RA patent/SG11201706718RA/en unknown
- 2016-02-19 KR KR1020177024303A patent/KR20170106483A/ko not_active Application Discontinuation
- 2016-02-19 CA CA2975413A patent/CA2975413A1/en not_active Abandoned
-
2017
- 2017-07-10 IL IL253405A patent/IL253405A0/en unknown
- 2017-07-20 ZA ZA2017/04948A patent/ZA201704948B/en unknown
- 2017-08-21 DO DO2017000196A patent/DOP2017000196A/es unknown
- 2017-08-22 SV SV2017005520A patent/SV2017005520A/es unknown
- 2017-08-23 CL CL2017002148A patent/CL2017002148A1/es unknown
- 2017-08-28 CO CONC2017/0008721A patent/CO2017008721A2/es unknown
- 2017-08-30 PH PH12017501560A patent/PH12017501560A1/en unknown
- 2017-09-01 EC ECIEPI201758071A patent/ECSP17058071A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12017501560A1 (en) | 2018-02-05 |
| CO2017008721A2 (es) | 2018-01-05 |
| AU2016228055B2 (en) | 2018-06-07 |
| KR20170106483A (ko) | 2017-09-20 |
| TN2017000372A1 (en) | 2019-01-16 |
| CN107406436A (zh) | 2017-11-28 |
| IL253405A0 (en) | 2017-09-28 |
| EP3265460A1 (en) | 2018-01-10 |
| US20180194755A1 (en) | 2018-07-12 |
| MX2017011087A (es) | 2017-11-10 |
| EP3265460A4 (en) | 2018-08-08 |
| JP2018507232A (ja) | 2018-03-15 |
| DOP2017000196A (es) | 2017-09-15 |
| CA2975413A1 (en) | 2016-09-09 |
| CR20170354A (es) | 2017-09-05 |
| WO2016138631A1 (en) | 2016-09-09 |
| ECSP17058071A (es) | 2017-10-31 |
| SV2017005520A (es) | 2018-08-27 |
| SG11201706718RA (en) | 2017-09-28 |
| ZA201704948B (en) | 2019-02-27 |
| US10196385B2 (en) | 2019-02-05 |
| BR112017015448A2 (pt) | 2018-01-30 |
| EA201791745A1 (ru) | 2018-01-31 |
| CL2017002148A1 (es) | 2018-04-13 |
| AU2016228055A1 (en) | 2017-08-17 |
| WO2016138821A1 (en) | 2016-09-09 |
| MA41641A (fr) | 2018-01-09 |
| CN107406436B (zh) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| PE20141996A1 (es) | Compuestos con actividad nematicida | |
| PE20160208A1 (es) | Compuestos de pirimidinodiona contra estados cardiacos | |
| PE20160524A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| PE20080061A1 (es) | Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3 | |
| PE20181269A1 (es) | Agonistas del receptor de apelina y metodos de uso | |
| PE20161396A1 (es) | Compuesto heterociclico | |
| PE20191020A1 (es) | Compuestos quimicos | |
| AR103048A1 (es) | Compuestos de uracilo que contienen un anillo de isoxazolina y las utilizaciones de esos compuestos | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| ES2721280T3 (es) | Nuevos inhibidores de la FYN quinasa | |
| PE20151072A1 (es) | Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa | |
| PE20061367A1 (es) | Nuevos derivados del fluoreno y composiciones que los contienen | |
| PE20170186A1 (es) | Nuevos compuestos | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| PE20200724A1 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| PE20070041A1 (es) | Amidas de acido pirazolcarboxilico | |
| PE20181015A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| PE20160802A1 (es) | Inhibidores de dgat1 de eter ciclico de cabeza de puente | |
| AR076098A1 (es) | Derivados de benzofurano | |
| PE20070122A1 (es) | Proceso para preparar derivados de piperazina azindoloxoacetica sustituida con triazol y nuevas formas de sal producidas de los mismos | |
| PE20140968A1 (es) | Derivados de benzamida sustituida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |